BOD Trademark

Trademark Overview


On Monday, March 16, 2020, a trademark application was filed for BOD with the United States Patent and Trademark Office. The USPTO has given the BOD trademark a serial number of 88835504. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Friday, September 17, 2021. This trademark is owned by Bod Australia Limited. The BOD trademark is filed in the Pharmaceutical Products category with the following description:

Nutritional supplements; dietary supplements; vitamin supplements; natural healthcare preparations for general health and well-being and for the treatment of metabolic diseases and disorders, namely, diabetes, type II diabetes, nephropathy, inflammation of the intestine, neuroinflammatory disorders, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism, obesity associated with diabetes, and for the treatment of pain, neuropathic pain, neurogenic pain, cancer pain, peri-operative pain, oncology, cancer symptoms, multiple sclerosis, spasticity, MS spasticity, convulsions, seizures, epilepsy, paediatric epilepsy, intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC), generalized epilepsy with febrile seizures plus (GEFS+), Dup15q syndrome, and Doose syndrome, bladder disfunction, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Alzheimer's, Dravet syndrome, Lennox-Gastaut syndrome (L...
bod

General Information


Serial Number88835504
Word MarkBOD
Filing DateMonday, March 16, 2020
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateFriday, September 17, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing5000 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Indication of Colors claimedColor is not claimed as a feature of the mark.
Description of MarkThe mark consists of the word BOD in a stylized font.
Goods and ServicesNutritional supplements; dietary supplements; vitamin supplements; natural healthcare preparations for general health and well-being and for the treatment of metabolic diseases and disorders, namely, diabetes, type II diabetes, nephropathy, inflammation of the intestine, neuroinflammatory disorders, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism, obesity associated with diabetes, and for the treatment of pain, neuropathic pain, neurogenic pain, cancer pain, peri-operative pain, oncology, cancer symptoms, multiple sclerosis, spasticity, MS spasticity, convulsions, seizures, epilepsy, paediatric epilepsy, intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC), generalized epilepsy with febrile seizures plus (GEFS+), Dup15q syndrome, and Doose syndrome, bladder disfunction, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Alzheimer's, Dravet syndrome, Lennox-Gastaut syndrome (LGS), spinal cord injury, head injury, bone disorders, chromosome disorders, inflammatory connective tissue diseases, arthritis, neurodegenerative diseases, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, cerebral palsy, brain, movement, ocular motility, peripheral neuropathy, neurogenic symptoms, hypoxicischemic encephalopathy, neonatal hypoxic encephalopathy, stroke, motion sickness, AIDS (HIV) and AIDS wasting, asthma, breathing disorders, hepatitis C, migraines, multiple sclerosis, analgesia, Tourette syndrome, bulimia, psychiatric disorders, namely, bipolar disorder, dementia, anxiety disorders, Alzheimer's disease, schizophrenia, and drug, alcohol and nicotine abuse, autism, nausea, vomiting, loss of appetite, muscle tension, muscle spasms, epilepsy, glaucoma, arthritis, Parkinson's disease, gastrointestinal illness, anxiety, bi-polar disorder, depression, insomnia, and for topical treatment of skin inflammation, namely, eczema, psoriasis, atopic dermatitis, acne, rosacea, lichen planus, bullous pemphigold, vasculitis, granuloma annulare and erythroderma; natural pharmaceutical preparations for general health and well-being and for the treatment of metabolic diseases and disorders, namely, diabetes, type II diabetes, nephropathy, inflammation of the intestine, neuroinflammatory disorders, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism, obesity associated with diabetes, and for the treatment of pain, neuropathic pain, neurogenic pain, cancer pain, peri-operative pain, oncology, cancer symptoms, multiple sclerosis, spasticity, MS spasticity, convulsions, seizures, epilepsy, paediatric epilepsy, intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC), generalized epilepsy with febrile seizures plus (GEFS+), Dup15q syndrome, and Doose syndrome, bladder disfunction, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Alzheimer's, Dravet syndrome, Lennox-Gastaut syndrome (LGS), spinal cord injury, head injury, bone disorders, chromosome disorders, inflammatory connective tissue diseases, arthritis, neurodegenerative diseases, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, cerebral palsy, brain, movement, ocular motility, peripheral neuropathy, neurogenic symptoms, hypoxicischemic encephalopathy, neonatal hypoxic encephalopathy, stroke, motion sickness, AIDS (HIV) and AIDS wasting, asthma, breathing disorders, hepatitis C, migraines, multiple sclerosis, analgesia, Tourette syndrome, bulimia, psychiatric disorders, namely, bipolar disorder, dementia, anxiety disorders, Alzheimer's disease, schizophrenia, and drug, alcohol and nicotine abuse, autism, nausea, vomiting, loss of appetite, muscle tension, muscle spasms, epilepsy, glaucoma, arthritis, Parkinson's disease, gastrointestinal illness, anxiety, bi-polar disorder, depression, insomnia, and for topical treatment of skin inflammation, namely, eczema, psoriasis, atopic dermatitis, acne, rosacea, lichen planus, bullous pemphigold, vasculitis, granuloma annulare and erythroderma; any the foregoing containing hemp extracts are derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, March 20, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBod Australia Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressDOUBLE BAY NSW2028
AU

Trademark Events


Event DateEvent Description
Friday, September 17, 2021ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Friday, September 17, 2021ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Saturday, March 6, 2021NOTIFICATION OF FINAL REFUSAL EMAILED
Saturday, March 6, 2021FINAL REFUSAL E-MAILED
Saturday, March 6, 2021FINAL REFUSAL WRITTEN
Thursday, March 4, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, March 3, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, March 3, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, September 5, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, September 5, 2020NON-FINAL ACTION E-MAILED
Saturday, September 5, 2020NON-FINAL ACTION WRITTEN
Monday, August 31, 2020ASSIGNED TO EXAMINER
Thursday, August 6, 2020PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Thursday, August 6, 2020TEAS VOLUNTARY AMENDMENT RECEIVED
Tuesday, June 9, 2020ASSIGNED TO EXAMINER
Monday, June 8, 2020ASSIGNED TO EXAMINER
Friday, March 20, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, March 19, 2020NEW APPLICATION ENTERED IN TRAM